PTGS2 and pituitary tumor: In the current study, no difference among the FPAs subtypes as a point of COX-2 expression was observed, although acromegaly tumor tissue and prolactinoma revealed the highest and lowest levels of COX-2 in endocrinologically active pituitary tumors, respectively.